The Therapeutic Values of Il-7/Il-7R and the Recombinant Derivatives in Glioma: A Narrative Review Publisher Pubmed



Hesari M¹ ; Attar Z^{2, 3} ; Soltanishirazi S⁴ ; Keshavarzian O⁵ ; Taheri R⁶ ; Tabrizi R⁷ ; Fouladseresht H⁴
Source: Journal of Interferon and Cytokine Research Published:2023

Abstract

Interleukin-7 (IL-7) is essential for maintaining the immune system’s defense functions by regulating the development and homeostasis of lymphocytes. Findings have shown the high efficacy of IL-7/IL-7 receptor (IL-7R)-based immunotherapy on various malignancies, with confirmation in both animal models and humans. In recent years, the progression-free survival and overall survival of patients suffering from gliomas significantly increased by introducing C7R-expressing chimeric antigen receptor (CAR)-T cells and long-acting IL-7 agonists such as NT-I7 (rhIL-7-hyFc, Efineptakin alfa). However, the effect of IL-7-based immunotherapies on the resistance of tumor cells to chemotherapy (when used simultaneously with chemotherapy agents) is still ambiguous and requires further studies. This article first reviews the pathophysiological roles of IL-7/IL-7R in tumors, focusing on gliomas. Subsequently, it discusses the therapeutic values of IL-7/IL-7R and the recombinant derivatives in gliomas. © Mary Ann Liebert, Inc.